硼替佐米为基础的治疗方案治疗华氏巨球蛋白血症15例的临床分析

侯楠; 安然; 侯健

doi:10.3969/j.issn.1006-0111.2016.05.020

硼替佐米为基础的治疗方案治疗华氏巨球蛋白血症15例的临床分析

doi: 10.3969/j.issn.1006-0111.2016.05.020

第二军医大学附属长征医院血液内科, 上海 200003

Clinical analysis of 15 patients with Waldenström macroglobulinemia received bortezomib-based treatment

Department of Hemopathology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China

摘要: 目的探讨以硼替佐米为基础的方案治疗华氏巨球蛋白血症（Waldenström macroglobulinemia，WM）的临床疗效及安全性。方法回顾性分析2008年12月至2015年10月收治的15例采用以硼替佐米为基础方案治疗的WM患者的临床资料。其中1例采用硼替佐米+地塞米松（BD）方案，3例采用硼替佐米+地塞米松+美罗华（RBD）方案，11例采用硼替佐米+地塞米松+环磷酰胺（BCD）方案，评价上述三方案的疗效及不良反应，并进行生存分析。结果治疗的总反应率及主要反应率分别为93.3%和80%[其中完全缓解（CR）1例、非常好的部分缓解（VGPR）2例、部分缓解（PR）9例、微小反应（MR）2例]。不良反应包括胃肠道副作用（53.3%）、白细胞减少（20%）、感染（20%）及外周神经病变（26.7%）。随访时间为3~85个月（中位数21个月），无进展生存（PFS）时间为3~36个月（中位数21个月），1年的PFS率分别为83.3%。生存分析显示IPSSWM分级为高危组（P=0.015）及用药后治疗反应小于PR（P=0.024）是影响WM患者PFS的危险因素。结论以硼替佐米为基础的治疗方案可有效治疗WM患者，IPSSWM分级体系及治疗反应可作为判断以硼替佐米为基础的治疗方案的WM患者疾病进展预后的参考因素。
- 硼替佐米 /
- 华氏巨球蛋白血症 /
- 疗效分析
Abstract: Objective To summarize the clinical experience of bortezomib-based treatment for Waldenström macroglobulinemia and evaluate the therapeutic efficacy and safety. Methods The clinical data were collected for 15 patients with Waldenström macroglobulinemia receiving bortezomib-based treatment from December 2008 to October 2015.Three therapeutic regimens included BD (bortezomib and dexamethasone) in one case, RBD (bortezomib, rituximab and dexamethasone) in three cases and BCD (bortezomib, dexamethasone and cyclophosphamide) in eleven cases.Responses, adverse reactions and survival analysis were evaluated respectively. Results The overall response rate and major response rate were 93.3% and 80% including CR 1 case, VGPR 2 cases, PR 9 cases and MR 2 cases. The common adverse events included gastrointestinal (53.3%), leukopenia (20%), infection (20%) and peripheral neuropathy (26.7%). After a median follow-up of 21 (3-85) months, the median PFS (progression-free survival) time was 21 (3-36) months and 1 year PFS rate was 83.3%. Survival analysis showed that two prognostic risk factors related to PFS were high-risk group based on international prognostic scoring system for WM(IPSSWM)(P=0.015) and the low response to treatment (P=0.024). Conclusion Bortezomib-based therapeutic regimensexhibited significant efficacyfor patients with WM. IPSSWM and the responses to treatment can be usedto monitor the disease progression and evaluate the therapeutic result.
- bortezomib /
- Waldenströ /
- m macroglobulinemia

[1]	侯健,彭利晖. 华氏巨球蛋白血症:循证医学新进展及共识更新[J]. 解放军医学杂志, 2013,38(9):705-709.
[2]	Roussel M, Lauwers-Cances V, Robillard N, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome[J]. J Clin Oncol, 2014,32(25):2712-2717.
[3]	Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia[J]. Semin Oncol, 2003,30(2):110-115.
[4]	Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenström macroglobulinemia[J]. Blood, 2009,113(18):4163-4170.
[5]	Anderson KC, Alsina M, Bensinger W, et al. Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013[J]. J Natl Compr Canc Netw, 2012,10(10):1211-1219.
[6]	Pascal L, Gay J, Willekens C, et al. Bortezomib and Waldenström's macroglobulinemia[J]. Expert Opin Pharmacother, 2009,10(5):909-916.
[7]	Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib[J]. Haematologica, 2005,90(12):1655-1658.
[8]	Treon SP, Hunter ZR, Matous J, et al.Multicenter clinical trial of bortezomib in relapsed/refractory Waldenström's macroglobulinemia: results of WMCTG Trial 03-248[J]. Clin Cancer Res, 2007,13(11):3320-3325.
[9]	Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenström's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group[J]. J Clin Oncol, 2007,25(12):1570-1575.
[10]	Chen C, Kouroukis CT, White D, et al. Bortezomib in relapsed or refractory Waldenström's macroglobulinemia[J]. Clin Lymphoma Myeloma, 2009,9(1):74-76.
[11]	Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180[J]. J Clin Oncol, 2009,27(23):3830-3835.
[12]	Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenström macroglobulinemia[J]. J Clin Oncol, 2010,28(8):1422-1428.
[13]	Ghobrial IM, Xie W, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia[J]. Am J Hematol, 2010,85(9):670-674.
[14]	Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial[J]. Blood, 2007,110(10):3557-3560.
[15]	Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib[J]. J Clin Oncol, 2006,24(19):3113-3120.
[16]	Yi S, Cui R, Li Z, et al. Distinct characteristics and new prognostic scoring system for Chinese patients with Waldenström macroglobulinemia[J]. Chin Med J (Engl), 2014,127(12):2327-2331.

[1]	李锐, 张倩倩, 王瑞冬, 高小峰. 国家集中带量采购政策下样本医院良性前列腺增生治疗药物使用情况分析 . 药学实践与服务, 2025, 43(2): 1-6. doi: 10.12206/j.issn.2097-2024.202408031
[2]	石晓萍, 吕迁洲, 李晓宇, 许青. 泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202401050
[3]	黄韵, 张正银, 金英, 郑怡菁, 李铁军, 孙莉莉. 耐碳青霉烯类肺炎克雷伯菌及大肠埃希菌临床分离株耐药性及耐药基因分析 . 药学实践与服务, 2024, 42(10): 439-444. doi: 10.12206/j.issn.2097-2024.202309059
[4]	刘丽艳, 余小翠, 孙传铎. 纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
[5]	张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英. 二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
[6]	史生辉, 石飞, 雷琼, 王亚峰, 吴雪花. 青藏高原肺结核合并念珠菌感染患者的病原菌分布特点及耐药率分析 . 药学实践与服务, 2024, 42(6): 260-262, 272. doi: 10.12206/j.issn.2097-2024.202304014
[7]	陈静, 何瑞华, 翁月, 徐熠, 刘静, 黄瑾. 基于网络药理学和分子对接技术探究定清片活性成分治疗白血病的作用机制 . 药学实践与服务, 2024, 42(11): 479-486. doi: 10.12206/j.issn.2097-2024.202401073
[8]	戴菲菲, 傅翔, 陈琼年, 俞苏纯. 上海某二级医院革兰阴性菌流行特征的回顾性分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202305005
[9]	刘依秦, 王超群, 邱娇娜. 胆宁片预处理在糖尿病患者结肠镜检查前的应用效果分析 . 药学实践与服务, 2024, 42(9): 407-410. doi: 10.12206/j.issn.2097-2024.202407037
[10]	瞿文君, 白若楠, 崔力, 周琰. 基于联合库存的公立医院多院区药品采购模式分析 . 药学实践与服务, 2024, 42(7): 315-318. doi: 10.12206/j.issn.2097-2024.202401002
[11]	宋红卫, 王燕, 方铭, 马云鹏, 钟超, 徐一新, 徐峰, 周婷. 2021−2023年我院药品不良反应的特点分析 . 药学实践与服务, 2024, 42(): 1-6. doi: 10.12206/j.issn.2097-2024.202404041
[12]	张晶晶, 索丽娜, 郑兆红. 89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
[13]	尹小娟, 台力丽, 肖俊峰, 季波. 铜绿假单胞菌合并按蚊伊丽莎白菌肺部感染的病例分析 . 药学实践与服务, 2024, 42(5): 223-226. doi: 10.12206/j.issn.2097-2024.202310042
[14]	刘汝雄, 杨万镇, 涂杰, 盛春泉. 铁死亡调控蛋白GPX4的小分子抑制剂研究进展 . 药学实践与服务, 2024, 42(9): 375-378. doi: 10.12206/j.issn.2097-2024.202312075
[15]	姚瑞阳, 于海征, 李耀盺, 张磊. 丹参FBXL 基因家族的鉴定和表达模式分析 . 药学实践与服务, 2024, 42(11): 461-470. doi: 10.12206/j.issn.2097-2024.202407034
[16]	张岩, 李炎君, 刘家荟, 邓娇, 原苑, 张敬一. 药物性肝损伤不良反应分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404034
[17]	凯丽比努尔·奥布力艾散, 李倩, 谢志, 贾文彦, 尹东锋. 星点设计-效应面法优化仑伐替尼混合胶束的制备工艺 . 药学实践与服务, 2024, 42(11): 495-502. doi: 10.12206/j.issn.2097-2024.202403019
[18]	陈春娟, 郑志新, 李骊. 平喘方联合孟鲁司特钠治疗儿童支气管哮喘患者的临床疗效观察 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202405035
[19]	崔晓林, 付晓菲, 杜艳红, 刘娟, 朱茜, 刘子祺. 临床药师参与吉瑞替尼致QTc间期延长的病例分析 . 药学实践与服务, 2024, 42(6): 263-266. doi: 10.12206/j.issn.2097-2024.202309050

点击查看大图

计量

文章访问数: 3576
HTML全文浏览量: 428
PDF下载量: 491
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

硼替佐米为基础的治疗方案治疗华氏巨球蛋白血症15例的临床分析

doi: 10.3969/j.issn.1006-0111.2016.05.020

Clinical analysis of 15 patients with Waldenström macroglobulinemia received bortezomib-based treatment

计量

硼替佐米为基础的治疗方案治疗华氏巨球蛋白血症15例的临床分析

doi: 10.3969/j.issn.1006-0111.2016.05.020

第二军医大学附属长征医院血液内科, 上海 200003

English Abstract

Clinical analysis of 15 patients with Waldenström macroglobulinemia received bortezomib-based treatment

Department of Hemopathology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China

全文HTML

目录

留言板

硼替佐米为基础的治疗方案治疗华氏巨球蛋白血症15例的临床分析

doi: 10.3969/j.issn.1006-0111.2016.05.020

Clinical analysis of 15 patients with Waldenström macroglobulinemia received bortezomib-based treatment

计量

出版历程

硼替佐米为基础的治疗方案治疗华氏巨球蛋白血症15例的临床分析

doi: 10.3969/j.issn.1006-0111.2016.05.020

第二军医大学附属长征医院血液内科, 上海 200003

English Abstract

Clinical analysis of 15 patients with Waldenström macroglobulinemia received bortezomib-based treatment

Department of Hemopathology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China

全文HTML

目录